Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3049–3072 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer
Interventions: Docetaxel,doxorubicin, cyclophosphamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 3,299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor, Malignant Tumor of Breast, Advanced Breast Cancer, Advanced Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration-resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Glioblastoma, Recurrent Glioblastoma
Interventions: NUV-422; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Tucson, Arizona • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Melanoma (Skin)
Interventions: Aspirin 81 mg, Aspirin 325mg, Placebo oral tablet; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypotrichosis
Interventions: Bimatoprost 0.03% solution, Vehicle solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Skin Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 1,889 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2026
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Harrison, New York • Hauppauge, New York + 1 more

Conditions: Psoriasis
Interventions: VTAMA® (tapinarof) Cream 1%; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Los Angeles, California • Boca Raton, Florida + 4 more

Conditions: Melanoma
Interventions: 852A; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Oklahoma City, Oklahoma

Conditions: Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Interventions: EB-101 Surgical application of RDEB wounds; Biological
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 12 Months and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Redwood City, California • Worcester, Massachusetts

Conditions: Acne Vulgaris
Interventions: BTX 1503, Vehicle; Drug
Lead sponsor: Botanix Pharmaceuticals; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 25
States / cities: Little Rock, Arkansas • Encino, California • Murrieta, California + 21 more

Conditions: Atopic Dermatitis, Food Allergy
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 1 Year to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
Interventions: Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose], Glucocorticoids [Reduced Dose]; Procedure · Other · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years and older
Enrollment: 704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 9
States / cities: Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Breast Cancer
Interventions: SAVI Scout MD system; Device
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer Survivor, Cancer Related Cognitive Difficulties, Sleep, Quality of Life
Interventions: Prolonged Nightly Fasting, Health Education Videos; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Neoplasms
Interventions: ForeCYTE Breast Aspirator; Device
Lead sponsor: Atossa Therapeutics, Inc.; Industry
Eligibility: 20 Years to 75 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Breast Cancer, Prostate Cancer, Patient Engagement, Patient Preference, Patient Satisfaction
Interventions: FOLLOW UP VISIT-TELEMEDICINE, FOLLOW UP VISIT-FACE TO FACE; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: Risankizumab, Autoinjector; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 22 more

Conditions: N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Interventions: Pimasertib, Dacarbazine; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 12 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1991
U.S. locations: 2
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Paclitaxel+Reparixin; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Scottsdale, Arizona • Fairway, Kansas • Ann Arbor, Michigan + 1 more

Conditions: Pressure Ulcer
Interventions: Casting using Gortex (waterproof) cast padding materials, Casting using cotton/cotton-poly cast padding materials; Other
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 1 Year to 18 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Nausea
Interventions: aprepitant, dexamethasone, granisetron hydrochloride, palonosetron hydrochloride, prochlorperazine, placebo; Drug
Lead sponsor: Joseph Roscoe; Other
Eligibility: 18 Years and older
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 16
States / cities: Mobile, Alabama • Decatur, Illinois • Wichita, Kansas + 13 more

Conditions: Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin, fludarabine phosphate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Providence Cancer Center, Earle A. Chiles Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced or Metastatic Breast Cancer
Interventions: LEE011, Buparlisib, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Lafayette, Indiana • Charleston, South Carolina + 2 more

Search by objective public record fields.

Docetaxel in Breast Cancer

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

Skin Barrier Abnormalities and Oxidative Stress Response

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid

TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Women At Risk: The High Risk Breast Cancer Program

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Cast Sores With Waterproof Vs. Standard Cast Padding

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.